Logo-jrip
Submitted: 02 Jul 2021
Accepted: 02 Nov 2021
ePublished: 17 Jan 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(1): e31928.
doi: 10.34172/jrip.2022.31928
  Abstract View: 338
  PDF Download: 38

Original

Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate

Asieh Aref ORCID logo, Samaneh Tirom* ORCID logo, Heshmatollah Shahbazian ORCID logo, Ali Ghorbani ORCID logo

1 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: Corresponding author: Samaneh Tirom, Email: tirom.sammane65@gmail.com, , Email: aref-a@ajums.ac.ir

Abstract

Introduction: Based on the evidence, rituximab may be an effective treatment for kidney transplantation for reducing panel-reactive antibody.

Objectives: This study was conducted to investigate the effect of rituximab on reducing the panel in transplant dialysis patients.

Patients and Methods: This is an interventional study that was conducted on 20 dialysis patients who were candidates for kidney transplantation. Patients first had a panel-reactive antibody test and patients with a panel-reactive antibody above the age of 30 were included in the study. First, rituximab was administered at a dose of one gram and then after two weeks, another dose of one gram was administered. Panel-reactive antibody was measured baseline, one and six months later.

Results: One and six months after stopping the drug, we found a significant decrease in the mean amount of reactive antibodies. Additionally, six months after stopping the drug, a significant decrease in the level of patients’ reactive antibodies in comparison to one month before taking the drug was detected (P<0.05).

Conclusion: The findings showed that treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients. However, more studies are needed to optimize rituximab injection protocols.


Implication for health policy/practice/research/medical education:

Treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients.

Please cite this paper as: Aref A, Tirom S, Shahbazian H, Ghorbani A. Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate. J Renal Inj Prev. 2023; 12(1): e31928. doi: 10.34172/jrip.2022.31928.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 335

Your browser does not support the canvas element.


PDF Download: 38

Your browser does not support the canvas element.